Turki Y. Alhazzazi, Ph.D. - Publications

2012 University of Michigan, Ann Arbor, Ann Arbor, MI 
Cell Biology, Oncology

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Alhazzazi TY, Kamarajan P, Xu Y, Ai T, Chen L, Verdin E, Kapila YL. A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells. Anticancer Research. 36: 49-60. PMID 26722027  0.56
2013 Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. Sirtuin-3 (SIRT3) and the Hallmarks of Cancer. Genes & Cancer. 4: 164-71. PMID 24020007 DOI: 10.1177/1947601913486351  0.56
2012 Kamarajan P, Alhazzazi TY, Danciu T, D'silva NJ, Verdin E, Kapila YL. Receptor-interacting protein (RIP) and Sirtuin-3 (SIRT3) are on opposite sides of anoikis and tumorigenesis. Cancer. 118: 5800-10. PMID 22674009 DOI: 10.1002/Cncr.27655  0.56
2011 Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? Biochimica Et Biophysica Acta. 1816: 80-8. PMID 21586315 DOI: 10.1016/J.Bbcan.2011.04.004  0.56
2011 Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ, Kapila YL. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer. 117: 1670-8. PMID 21472714 DOI: 10.1002/Cncr.25676  0.56
2011 Kamarajan P, Alhazzazi T, D'Silva N, Verdin E, Kapila Y. Abstract 4768: Receptor interacting protein (RIP) and Sirtuin-3 (SIRT3) on opposite sides of anoikis resistance and promotes tumorigenesis Cancer Research. 71: 4768-4768. DOI: 10.1158/1538-7445.Am2011-4768  0.56
Show low-probability matches.